Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Theratechnologies Inc > Oramed Reports Positive Top-Line Results from Phase 2 NASH
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(20)
•••
Comment by TH1902on Sep 13, 2022 11:15pm
110 Views
Post# 34960952

RE:RE:RE:Oramed Reports Positive Top-Line Results from Phase 2 NASH

RE:RE:RE:Oramed Reports Positive Top-Line Results from Phase 2 NASHThx QWERTY, just posted it after a quick read, doing some more reading about the company now as I know very little about them.  Some results expected in Jan.2023... 

qwerty22 wrote:

It didn't shoot up because they reported their efficacy data as a "trend". Which tells us virtually nothing.

 

TH1902 wrote: Anyone know this company?  I don't know of them, wondering why it didn't shoot up like AKERO after this pre-market news today.  Ticker ORMP 
 

 

TH1902 wrote:


Oramed Reports Positive Top-Line Results from Phase 2 NASH Trial with its ORMD-0801, Oral Insulin Candidate


https://finance.yahoo.com/news/oramed-reports-positive-top-line-124000024.html
 

 




<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities